July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Graham Collins: TRANSFORM Study – Liso-Cel vs Standard 2nd Line in 1st Relapse Large B-Cell NHL
Jul 9, 2025, 16:58

Graham Collins: TRANSFORM Study – Liso-Cel vs Standard 2nd Line in 1st Relapse Large B-Cell NHL

Graham Collins, Associate Professor, Haematology and Lymphoma Specialist at Oxford Cancer and Haematology Centre, shared a post on X:

“Kamdar et al; 3y FU of TRANSFORM study – Liso-cel vs standard 2nd line in 1st relapse large B-cell NHL.

Impressive PFS & EFS benefit Trend to OS but not stat significant. 66% crossed over to liso-cel from control arm.

No new tox signal.”

Title: Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study

Authors: Manali Kamdar, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Victor A. Chow, Sandrine Montheard, Josu Santamaria, Silvia Colicino, Ken Ogasawara, Lara Stepan, Fei Fei Liu, Jeremy S. Abramson

Read Full Article.

Transform study

More posts featuring Graham Collins on OncoDaily.